Enzyme-targeting drug stops tumour growth in multiple cancers
An enzyme critically associated with tumour growth has long been a target for researchers, but until now it has been difficult to successfully inhibit it.
Source: labonline.com.au
Incyclix Bio News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Incyclix Bio. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Incyclix Bio Today - Breaking & Trending Today
CDK4/6 Inhibitor Selection and Sequencing Continue to Evolve in HR+ Breast Cancer
Sarah Sammons, MD, discusses the evolving role of CDK4/6 inhibitors in hormone receptor–positive breast cancer, the future of antibody-drug conjugates in triple-negative breast cancer, and the importance of educating patients about their available treatment options so they can share in the decision-making process.
Source: onclive.com
Incyclix Bio Raises $30M in Series B Financing
FinSMEs is the financial news site dedicated to covering venture capital, private equity, and merger and acquisition deals in real time!
Source: finsmes.com
$30 Million In New Funding Signals "Better Day to Cure Cancer" for Incyclix | North Carolina Biotechnology Center
Newly minted RTP cancer therapeutics developer Incyclix Bio has just received $30 million in Series B financing.
Source: ncbiotech.org
Incyclix Bio Raises $30M in Series B Financing
The company will use the funding to initiate a Phase I/II study of its CDK2 inhibitor in CDK4/6-resistant breast cancer and cyclin E-overexpressed ovarian cancer.
Source: precisiononcologynews.com